- id: extra_adrd_differential_013
  name: ADRD Differential Diagnoses
  type: keyword_list
  content: 'Differential diagnoses for cognitive impairment: Delirium, Acute confusional
    state, Depression, Pseudodementia, Normal aging, Age-related cognitive decline,
    Benign senescent forgetfulness, Medication-induced cognitive impairment, Normal
    pressure hydrocephalus, NPH, Brain tumor, Subdural hematoma, Chronic subdural
    hematoma, Alcohol-related dementia, Wernicke-Korsakoff, Autoimmune encephalitis,
    Limbic encephalitis, Creutzfeldt-Jakob disease, CJD, Huntington disease, Progressive
    supranuclear palsy, PSP, Corticobasal degeneration, CBD, Multiple sclerosis, Parkinson
    disease dementia, PDD'
  metadata:
    category: differential_diagnosis
    diagnosis: adrd
    priority: CRITICAL
    domain: neurology
  created_at: '2025-11-15T00:00:00'
- id: extra_nstemi_001
  type: diagnostic_criteria
  content: 'NSTEMI (Non-ST Elevation MI): Acute coronary syndrome with myocardial
    necrosis WITHOUT ST elevation. Diagnosis requires: (1) Symptoms of ischemia (chest
    pain >20min, dyspnea, diaphoresis); (2) Elevated cardiac biomarkers (troponin
    rise/fall pattern); (3) ECG changes (ST depression, T inversion, no ST elevation).
    TIMI Risk Score: 0-7 (age≥65, ≥3 CAD risk factors, known CAD, ASA use, severe
    angina, ST changes, elevated markers). High-risk features: ongoing pain, hemodynamic
    instability, arrhythmia, elevated troponin >10x ULN, dynamic ST changes. Treatment:
    dual antiplatelet (ASA + P2Y12 inhibitor), anticoagulation (heparin/enoxaparin),
    BB, statin, early invasive strategy (cath <24-48h for high-risk). GRACE score
    predicts mortality. Complications: cardiogenic shock, VT/VF, HF, recurrent ischemia.'
  metadata:
    category: cardiovascular
    diagnosis: nstemi
    priority: CRITICAL
    icd10_codes:
    - I214
    icd9_codes:
    - '41071'
  created_at: '2025-11-10T00:00:00'
  name: NSTEMI - Diagnostic Criteria & Management
- id: heart_failure_criteria
  type: diagnostic_criteria
  name: Heart Failure - Classification and Diagnostic Criteria
  content: "HEART FAILURE (HF) - CLINICAL SYNDROME:\n\nDEFINITION:\n- Inability of\
    \ heart to pump sufficient blood to meet metabolic demands\n- Structural or functional\
    \ cardiac abnormality\n\nCLASSIFICATION BY EJECTION FRACTION:\n- HFrEF: LVEF ≤40%\
    \ (reduced EF, systolic dysfunction)\n- HFmrEF: LVEF 41-49% (mildly reduced EF)\n\
    - HFpEF: LVEF ≥50% (preserved EF, diastolic dysfunction)\n\nCLASSIFICATION BY\
    \ TIMING:\n- Acute: New onset or decompensation of chronic HF\n- Chronic: Stable\
    \ symptoms\n- Acute-on-chronic: Decompensation of known chronic HF\n\nNYHA FUNCTIONAL\
    \ CLASS:\n- Class I: No limitation, asymptomatic\n- Class II: Slight limitation,\
    \ comfortable at rest\n- Class III: Marked limitation, comfortable only at rest\n\
    - Class IV: Symptoms at rest, inability to carry out any activity\n\nDIAGNOSTIC\
    \ CRITERIA (Framingham):\nMajor: PND, neck vein distention, rales, cardiomegaly,\
    \ acute pulmonary edema, S3 gallop, JVP >16cm, hepatojugular reflux\nMinor: Ankle\
    \ edema, night cough, dyspnea on exertion, hepatomegaly, pleural effusion, tachycardia\
    \ ≥120\nRequires: 2 major OR 1 major + 2 minor\n\nBIOMARKERS:\n- BNP >100 pg/mL\
    \ or NT-proBNP >125 pg/mL (suggests HF)\n- Higher levels indicate worse prognosis\n\
    \nECHOCARDIOGRAPHY (Essential):\n- Assess LVEF, wall motion, valve function, chamber\
    \ sizes\n\nTREATMENT (HFrEF):\n- Guideline-directed medical therapy (GDMT):\n\
    \  1. ACE-I/ARB or ARNI (sacubitril/valsartan)\n  2. Beta-blocker (carvedilol,\
    \ metoprolol succinate, bisoprolol)\n  3. Mineralocorticoid receptor antagonist\
    \ (spironolactone/eplerenone)\n  4. SGLT2 inhibitor (dapagliflozin, empagliflozin)\n\
    - Diuretics for volume overload\n- Consider: ICD, CRT, cardiac transplant"
  metadata:
    category: cardiovascular
    diagnosis: heart_failure
    priority: CRITICAL
    source: ACC/AHA HF Guidelines 2022
- id: extra_adrd_imaging_007
  name: ADRD Neuroimaging Findings
  type: keyword_list
  content: 'Neuroimaging findings in ADRD: Brain MRI, Brain CT, Head CT, Head MRI,
    PET scan, FDG-PET, Amyloid PET, Tau PET, SPECT, Cerebral atrophy, Brain atrophy,
    Cortical atrophy, Medial temporal atrophy, Hippocampal atrophy, Entorhinal atrophy,
    Frontal atrophy, Temporal atrophy, Parietal atrophy, Ventricular enlargement,
    White matter hyperintensities, WMH, Leukoaraiosis, Lacunar infarct, Lacunes, Stroke,
    Infarct, Territorial infarct, Microbleeds, Cerebral microbleeds, Cerebrovascular
    disease, Small vessel disease, Hypometabolism, Temporo-parietal hypometabolism,
    Amyloid positive, Amyloid negative, Tau deposition'
  metadata:
    category: imaging
    diagnosis: adrd
    priority: HIGH
    domain: radiology
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_functional_002
  name: ADRD Functional Assessment Terms
  type: keyword_list
  content: 'Functional status terminology for ADRD classification: ADL (Activities
    of Daily Living), IADL (Instrumental Activities of Daily Living), Functional decline,
    Functional impairment, Independent in ADLs, Needs assistance, Bathing assistance,
    Dressing assistance, Toileting assistance, Managing finances, Managing medications,
    Meal preparation, Driving ability, Shopping ability, Functional independence,
    Katz Index, Lawton Scale, FAQ (Functional Activities Questionnaire)'
  metadata:
    category: functional_assessment
    diagnosis: adrd
    priority: CRITICAL
    domain: activities_of_daily_living
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_neuro_006
  name: ADRD Neurological Examination Findings
  type: keyword_list
  content: 'Neurological examination findings in ADRD: Parkinsonism, Rigidity, Bradykinesia,
    Tremor, Resting tremor, Gait disturbance, Gait abnormality, Shuffling gait, Falls,
    Balance problems, Postural instability, Primitive reflexes, Grasp reflex, Snout
    reflex, Palmomental reflex, Focal neurological deficit, Hemiparesis, Weakness,
    Sensory loss, Extrapyramidal signs, Myoclonus, Seizures'
  metadata:
    category: examination
    diagnosis: adrd
    priority: MEDIUM
    domain: neurology
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_criteria_012
  name: ADRD Diagnostic Criteria References
  type: keyword_list
  content: 'Diagnostic criteria for ADRD: NIA-AA criteria, NIA-AA, National Institute
    on Aging, Alzheimer''s Association criteria, DSM-5, DSM-IV, ICD-10, ICD-11, NINDS-AIREN,
    NINCDS-ADRDA, DLB consortium criteria, Lewy body criteria, FTD criteria, Rascovsky
    criteria, McKhann criteria'
  metadata:
    category: diagnostic_criteria
    diagnosis: adrd
    priority: HIGH
    domain: guidelines
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_cognitive_001
  name: ADRD Cognitive Assessment Terms
  type: keyword_list
  content: 'Cognitive assessment terminology for ADRD classification: MMSE (Mini-Mental
    State Examination), MoCA (Montreal Cognitive Assessment), CDR (Clinical Dementia
    Rating), Clock Drawing Test, Neuropsychological testing, Cognitive screening,
    Memory testing, Executive function testing, Trail Making Test, Boston Naming Test,
    HVLT (Hopkins Verbal Learning Test), Rey Auditory Verbal Learning, Digit Span,
    Verbal fluency, Category fluency, Semantic memory, Episodic memory, Working memory,
    Attention span, Processing speed'
  metadata:
    category: cognitive_assessment
    diagnosis: adrd
    priority: HIGH
    domain: neuropsychology
  created_at: '2025-11-15T00:00:00'
- id: geriatric_considerations
  name: Geriatric Considerations
  type: tip
  content: 'Polypharmacy common - review medications regularly (deprescribing). Altered
    pharmacokinetics/dynamics: Lower GFR affects drug clearance, increased sensitivity
    to CNS medications. Fall risk assessment. Frailty screening. Functional status
    (ADLs/IADLs). Cognitive screening (MMSE, MoCA). Social support. Goals of care
    discussions.'
  metadata:
    category: geriatrics
    subcategory: comprehensive_assessment
    priority: medium
  created_at: '2025-11-05T02:53:21.388550'
- id: beers_criteria_for_older_adults
  name: Beers Criteria for Older Adults
  type: guideline
  content: 'Potentially inappropriate medications in elderly: Anticholinergics (confusion,
    falls), Benzodiazepines (falls, cognitive impairment), NSAIDs (GI bleed, renal
    injury), PPIs long-term (fractures, C.diff), First-gen antihistamines, Sliding
    scale insulin. Consider alternatives or lowest effective dose.'
  metadata:
    category: geriatrics
    subcategory: medication_safety
    priority: medium
  created_at: '2025-11-05T02:53:21.388828'
- id: chest_pain_criteria
  type: diagnostic_criteria
  name: Chest Pain - Evaluation and Workup
  content: 'CHEST PAIN EVALUATION:


    IMMEDIATE ASSESSMENT:

    - Life-threatening causes (ACS, PE, aortic dissection, tension pneumothorax, tamponade)

    - Character: pressure/squeezing (cardiac), sharp/pleuritic (PE/pericarditis),
    tearing (dissection)

    - Location: substernal (cardiac), left-sided (cardiac/GI), positional (MSK/pericarditis)

    - Radiation: left arm/jaw (cardiac), back (dissection/pancreatitis)

    - Associated symptoms: dyspnea, diaphoresis, nausea, syncope


    RISK STRATIFICATION:

    - HEART Score: 0-3 (low risk), 4-6 (moderate), 7-10 (high)

    - TIMI Score for UA/NSTEMI: 0-2 (low), 3-4 (moderate), 5-7 (high)


    WORKUP:

    - ECG within 10 minutes of arrival

    - Cardiac biomarkers: Troponin I/T (serial if initial negative)

    - Chest X-ray

    - Consider: D-dimer (if PE suspected), CTA chest (dissection/PE)


    DIFFERENTIAL DIAGNOSIS:

    1. Cardiac: ACS, stable angina, pericarditis, myocarditis

    2. Vascular: Aortic dissection, PE

    3. Pulmonary: Pneumonia, pneumothorax, pleuritis

    4. GI: GERD, esophageal spasm, peptic ulcer

    5. MSK: Costochondritis, muscle strain

    6. Psychiatric: Panic disorder, anxiety'
  metadata:
    category: cardiovascular
    diagnosis: chest_pain
    priority: CRITICAL
    source: AHA/ACC Guidelines
- id: extra_adrd_symptoms_004
  name: ADRD Cognitive Symptoms
  type: keyword_list
  content: 'Cognitive symptom terminology: Memory loss, Memory impairment, Forgetfulness,
    Short-term memory loss, Long-term memory loss, Recent memory loss, Remote memory
    loss, Amnesia, Disorientation, Confused, Confusion, Word-finding difficulty, Anomia,
    Aphasia, Language impairment, Getting lost, Visuospatial deficit, Executive dysfunction,
    Poor judgment, Impaired reasoning, Abstract thinking deficit, Apraxia, Agnosia,
    Difficulty concentrating, Attention deficit, Mental slowing, Bradyphrenia'
  metadata:
    category: symptoms
    diagnosis: adrd
    priority: HIGH
    domain: cognitive
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_behavioral_005
  name: ADRD Behavioral and Psychiatric Symptoms (BPSD)
  type: keyword_list
  content: 'Behavioral and psychiatric symptoms of dementia: BPSD, Behavioral symptoms,
    Agitation, Aggression, Irritability, Apathy, Depression, Depressed mood, Anxiety,
    Hallucinations, Visual hallucinations, Seeing things, Delusions, Paranoia, Paranoid,
    Suspiciousness, Psychosis, Sundowning, Sleep disturbance, Insomnia, Wandering,
    Disinhibition, Inappropriate behavior, Repetitive behaviors, Compulsive behaviors,
    REM sleep behavior disorder, Acting out dreams'
  metadata:
    category: symptoms
    diagnosis: adrd
    priority: HIGH
    domain: neuropsychiatric
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_vascular_010
  name: ADRD Vascular Risk Factors
  type: keyword_list
  content: 'Vascular risk factors for dementia: Hypertension, High blood pressure,
    Diabetes, Diabetes mellitus, Hyperglycemia, Hyperlipidemia, High cholesterol,
    Dyslipidemia, Atrial fibrillation, AFib, Stroke history, TIA, Transient ischemic
    attack, Coronary artery disease, CAD, Myocardial infarction, Heart attack, Smoking,
    Tobacco use, Obesity, Metabolic syndrome'
  metadata:
    category: risk_factors
    diagnosis: adrd
    priority: HIGH
    domain: cardiovascular
  created_at: '2025-11-15T00:00:00'
- id: atrial_fibrillation_criteria
  type: diagnostic_criteria
  name: Atrial Fibrillation - Diagnosis and Management
  content: 'ATRIAL FIBRILLATION (AFib):


    DEFINITION:

    - Supraventricular tachyarrhythmia with uncoordinated atrial activation

    - Irregular, rapid ventricular response


    ECG CRITERIA:

    - Irregularly irregular RR intervals

    - No distinct P waves

    - Atrial rate 350-600 bpm

    - Variable ventricular rate (typically 80-180 bpm if untreated)


    CLASSIFICATION:

    - Paroxysmal: Self-terminating, usually <7 days

    - Persistent: Lasting >7 days or requiring cardioversion

    - Long-standing persistent: Continuous >12 months

    - Permanent: Accepted, no further rhythm control attempts


    CLINICAL PRESENTATION:

    - May be asymptomatic (found incidentally)

    - Palpitations, dyspnea, fatigue, dizziness

    - Heart failure symptoms, syncope


    COMPLICATIONS:

    - Stroke/systemic embolism (5x increased risk)

    - Heart failure (AFib-induced cardiomyopathy)

    - Cognitive impairment


    STROKE RISK STRATIFICATION (CHA2DS2-VASc):

    - C: CHF (1 point)

    - H: Hypertension (1)

    - A2: Age ≥75 (2)

    - D: Diabetes (1)

    - S2: Prior stroke/TIA/thromboembolism (2)

    - V: Vascular disease (1)

    - A: Age 65-74 (1)

    - Sc: Sex category female (1)

    Score ≥2 (men) or ≥3 (women): Anticoagulation recommended


    BLEEDING RISK (HAS-BLED):

    - H: Hypertension, A: Abnormal renal/liver, S: Stroke, B: Bleeding, L: Labile
    INR, E: Elderly >65, D: Drugs/alcohol

    - Score ≥3: High bleeding risk (caution, not contraindication)


    MANAGEMENT:

    1. Rate control: Beta-blocker, CCB (diltiazem/verapamil), digoxin

    2. Rhythm control: Cardioversion, antiarrhythmics, catheter ablation

    3. Anticoagulation: DOACs preferred (apixaban, rivaroxaban, dabigatran, edoxaban)
    vs warfarin

    4. Treat underlying causes'
  metadata:
    category: cardiovascular
    diagnosis: atrial_fibrillation
    priority: HIGH
    source: AHA/ACC/HRS AFib Guidelines 2023
- id: extra_adrd_medications_011
  name: ADRD Medications
  type: keyword_list
  content: 'Medications related to dementia (treatment and causative): Donepezil,
    Aricept, Rivastigmine, Exelon, Galantamine, Razadyne, Memantine, Namenda, Cholinesterase
    inhibitor, Anticholinergic, Benzodiazepine, Opioid, Sedative, Antipsychotic, Antidepressant,
    SSRI, SNRI'
  metadata:
    category: medications
    diagnosis: adrd
    priority: MEDIUM
    domain: pharmacology
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_biomarkers_008
  name: ADRD Biomarkers
  type: keyword_list
  content: 'Biomarker terminology for ADRD: CSF biomarkers, Cerebrospinal fluid, Amyloid
    beta, Abeta, Aβ42, Total tau, t-tau, Phospho-tau, p-tau, Tau/Abeta ratio, ATN
    framework, Amyloid PET, Pittsburgh compound B, PIB, Florbetapir, Flutemetamol,
    Plasma biomarkers, Blood biomarkers, p-tau181, p-tau217'
  metadata:
    category: biomarkers
    diagnosis: adrd
    priority: HIGH
    domain: laboratory
  created_at: '2025-11-15T00:00:00'
- id: fall_risk_assessment
  name: Fall Risk Assessment
  type: criteria
  content: 'Risk factors: Age >65, prior falls, mobility impairment, visual impairment,
    polypharmacy (especially sedatives, antihypertensives), environmental hazards,
    orthostatic hypotension, cognitive impairment. Screen with Timed Up and Go (>12
    sec abnormal). Morse Fall Scale in hospitals. Multifactorial interventions.'
  metadata:
    category: geriatrics
    subcategory: fall_prevention
    priority: medium
  created_at: '2025-11-05T02:53:21.389652'
- id: extra_adrd_dementia_003
  name: ADRD Dementia Types and Diagnoses
  type: keyword_list
  content: 'Dementia diagnosis terminology: Alzheimer disease, Alzheimers, Alzheimer''s,
    AD, Dementia, Vascular dementia, VaD, Multi-infarct dementia, Lewy body dementia,
    LBD, Dementia with Lewy bodies, DLB, Frontotemporal dementia, FTD, Pick disease,
    Primary progressive aphasia, Semantic dementia, Behavioral variant FTD, bvFTD,
    Mixed dementia, Mild cognitive impairment, MCI, Amnestic MCI, Non-amnestic MCI,
    Neurocognitive disorder, Major neurocognitive disorder, Mild neurocognitive disorder,
    Senile dementia, Dementia NOS'
  metadata:
    category: diagnosis
    diagnosis: adrd
    priority: CRITICAL
    domain: neurology
  created_at: '2025-11-15T00:00:00'
- id: extra_adrd_reversible_009
  name: ADRD Reversible Causes and Laboratory Tests
  type: keyword_list
  content: 'Reversible causes and laboratory workup for cognitive impairment: Vitamin
    B12, B12 deficiency, Folate deficiency, Thyroid disorder, Hypothyroidism, TSH,
    Free T4, Metabolic panel, Electrolyte imbalance, Hyponatremia, Hypercalcemia,
    Renal function, Creatinine, Liver function, Hepatic encephalopathy, RPR, VDRL,
    Syphilis, HIV, Lyme disease, CBC, Anemia, Inflammatory markers, ESR, CRP'
  metadata:
    category: laboratory
    diagnosis: adrd
    priority: CRITICAL
    domain: differential_diagnosis
  created_at: '2025-11-15T00:00:00'
- id: psychosis_criteria
  type: diagnostic_criteria
  name: Psychosis - Differential Diagnosis and Management
  content: "PSYCHOTIC DISORDERS:\n\nDEFINITION OF PSYCHOSIS:\n- Loss of contact with\
    \ reality\n- Impaired reality testing\n\nCORE SYMPTOMS:\n\n1. HALLUCINATIONS:\n\
    \   - Perceptions without external stimulus\n   - Auditory (most common in schizophrenia):\
    \ Voices, commands\n   - Visual (suggest organic cause: delirium, substance)\n\
    \   - Tactile, olfactory, gustatory\n\n2. DELUSIONS:\n   - Fixed false beliefs\
    \ despite contrary evidence\n   - Persecutory, grandiose, referential, somatic,\
    \ nihilistic\n   - Bizarre vs non-bizarre\n\n3. DISORGANIZED THINKING:\n   - Formal\
    \ thought disorder\n   - Loose associations, tangentiality, word salad\n\n4. GROSSLY\
    \ DISORGANIZED OR CATATONIC BEHAVIOR\n\n5. NEGATIVE SYMPTOMS:\n   - Affective\
    \ flattening, alogia, avolition, anhedonia\n\nDIFFERENTIAL DIAGNOSIS:\n\nPRIMARY\
    \ PSYCHOTIC DISORDERS:\n\n1. SCHIZOPHRENIA (DSM-5):\n   - Duration ≥6 months\n\
    \   - ≥2 symptoms (≥1 must be delusions, hallucinations, or disorganized speech):\n\
    \     * Delusions, hallucinations, disorganized speech, grossly disorganized/catatonic\
    \ behavior, negative symptoms\n   - Significant functional impairment\n   - Not\
    \ due to substance or medical condition\n   \n   Subtypes (historical, no longer\
    \ in DSM-5):\n   - Paranoid, disorganized, catatonic, undifferentiated, residual\n\
    \n2. SCHIZOAFFECTIVE DISORDER:\n   - Schizophrenia criteria + major mood episode\
    \ (depression or mania)\n   - Delusions/hallucinations ≥2 weeks WITHOUT mood symptoms\n\
    \   - Mood symptoms present for majority of illness\n\n3. BRIEF PSYCHOTIC DISORDER:\n\
    \   - Psychotic symptoms lasting 1 day to 1 month\n   - Full return to baseline\n\
    \   - Often follows stressor\n\n4. SCHIZOPHRENIFORM DISORDER:\n   - Schizophrenia\
    \ symptoms lasting 1-6 months\n   - May or may not have functional impairment\n\
    \n5. DELUSIONAL DISORDER:\n   - ≥1 non-bizarre delusion for ≥1 month\n   - Otherwise\
    \ normal functioning\n   - No prominent hallucinations\n   - Types: Erotomanic,\
    \ grandiose, jealous, persecutory, somatic, mixed\n\nSECONDARY PSYCHOSIS (Must\
    \ rule out):\n\n1. SUBSTANCE-INDUCED:\n   - Intoxication: Stimulants (cocaine,\
    \ amphetamines), cannabis, hallucinogens, PCP\n   - Withdrawal: Alcohol, benzodiazepines\n\
    \   - Medication: Corticosteroids, anticholinergics, dopamine agonists, stimulants\n\
    \n2. MEDICAL CONDITIONS:\n   - Neurologic: Seizures, tumors, stroke, dementia,\
    \ encephalitis, MS\n   - Metabolic: Thyroid disorders, vitamin B12 deficiency,\
    \ porphyria\n   - Autoimmune: Lupus, anti-NMDA receptor encephalitis\n   - Infectious:\
    \ HIV, syphilis, Lyme disease\n   - Endocrine: Cushing's, hyperthyroidism, hypoglycemia\n\
    \n3. MOOD DISORDERS WITH PSYCHOTIC FEATURES:\n   - Major depression with psychotic\
    \ features (mood-congruent or incongruent)\n   - Bipolar disorder, manic episode\
    \ with psychotic features\n\nWORKUP FOR FIRST-EPISODE PSYCHOSIS:\n\nLaboratory:\n\
    - CBC, CMP (electrolytes, glucose, renal, hepatic)\n- TSH, vitamin B12, folate\n\
    - RPR/VDRL (syphilis)\n- HIV\n- Urine drug screen\n- Pregnancy test (if applicable)\n\
    - Consider: Ceruloplasmin (Wilson's), ANA, ESR (autoimmune), ammonia\n\nImaging:\n\
    - Brain MRI (preferred) or CT\n- Rule out structural lesions, demyelination, stroke\n\
    \nAdditional:\n- EEG if concern for seizures\n- Lumbar puncture if infectious/inflammatory\
    \ concern\n\nTREATMENT:\n\nACUTE MANAGEMENT:\n\n1. SAFETY ASSESSMENT:\n   - Risk\
    \ to self (suicide): 5% lifetime risk in schizophrenia\n   - Risk to others (violence):\
    \ Assess command hallucinations, paranoia\n   - Involuntary hospitalization if\
    \ imminent danger\n\n2. ANTIPSYCHOTICS:\n   \n   Typical (First-generation):\n\
    \   - Haloperidol 5-10mg PO/IM (onset 30-60min)\n   - Mechanism: D2 receptor antagonism\n\
    \   - Side effects: EPS (dystonia, akathisia, parkinsonism), tardive dyskinesia,\
    \ hyperprolactinemia, NMS\n   \n   Atypical (Second-generation) - Preferred:\n\
    \   - Risperidone 2-6mg/day\n   - Olanzapine 10-20mg/day (IM available for agitation)\n\
    \   - Quetiapine 300-800mg/day\n   - Aripiprazole 10-30mg/day\n   - Ziprasidone,\
    \ paliperidone, lurasidone\n   - Mechanism: D2 + 5-HT2A antagonism\n   - Side\
    \ effects: Metabolic (weight gain, diabetes, dyslipidemia), sedation, QTc prolongation\n\
    \   \n   Clozapine:\n   - Reserved for treatment-resistant (failed ≥2 trials)\n\
    \   - Most effective but requires monitoring (ANC, metabolic)\n   - Risk of agranulocytosis\
    \ (1%)\n\n3. AGITATION:\n   - Verbal de-escalation first\n   - Benzodiazepines:\
    \ Lorazepam 1-2mg PO/IM\n   - Antipsychotic + benzodiazepine combination\n   -\
    \ Avoid excessive sedation\n\nCHRONIC MANAGEMENT:\n\n1. MAINTENANCE ANTIPSYCHOTICS:\n\
    \   - Continue indefinitely (high relapse risk if discontinued)\n   - Lowest effective\
    \ dose\n   - Long-acting injectable (LAI) if adherence issues\n\n2. MONITORING:\n\
    \   - Metabolic: Weight, BMI, fasting glucose, lipids (baseline, 3mo, annually)\n\
    \   - Movement disorders: AIMS scale\n   - Prolactin if symptoms\n   - QTc if\
    \ on QT-prolonging agent\n\n3. PSYCHOSOCIAL:\n   - Cognitive behavioral therapy\
    \ (CBT) for psychosis\n   - Social skills training\n   - Supported employment/education\n\
    \   - Family psychoeducation\n   - Assertive community treatment (ACT) teams\n\
    \n4. COMORBIDITIES:\n   - Substance use (very common, 50%)\n   - Depression (treat\
    \ with antidepressant + antipsychotic)\n   - Anxiety\n\nPROGNOSIS:\n- Schizophrenia:\
    \ Chronic, relapsing\n- Better prognosis: Later onset, female, acute onset, good\
    \ premorbid function, mood symptoms\n- Worse prognosis: Early onset, male, insidious\
    \ onset, negative symptoms, substance use\n- Suicide risk: 5% lifetime\n- Reduced\
    \ life expectancy (10-20 years) due to CV disease, metabolic syndrome"
  metadata:
    category: psychiatric
    diagnosis: psychosis
    priority: HIGH
    source: DSM-5, APA Practice Guidelines for Schizophrenia
- id: alcohol_use_disorder_criteria
  type: diagnostic_criteria
  name: Alcohol Use Disorder - DSM-5 Criteria and Management
  content: "ALCOHOL USE DISORDER (AUD) - DSM-5:\n\nDIAGNOSTIC CRITERIA:\n≥2 symptoms\
    \ within 12-month period:\n\n1. Alcohol taken in larger amounts or longer than\
    \ intended\n2. Persistent desire or unsuccessful efforts to cut down\n3. Great\
    \ deal of time spent obtaining, using, or recovering from alcohol\n4. Craving\
    \ or strong desire to use alcohol\n5. Recurrent use resulting in failure to fulfill\
    \ major obligations\n6. Continued use despite social/interpersonal problems\n\
    7. Important activities given up or reduced\n8. Recurrent use in physically hazardous\
    \ situations\n9. Continued use despite physical/psychological problems\n10. Tolerance\
    \ (need for increased amounts or diminished effect)\n11. Withdrawal symptoms or\
    \ alcohol taken to relieve withdrawal\n\nSEVERITY:\n- Mild: 2-3 criteria\n- Moderate:\
    \ 4-5 criteria\n- Severe: ≥6 criteria\n\nSCREENING TOOLS:\n\nCAGE (≥2 positive\
    \ suggests problem):\n- Cut down: Felt need to cut down?\n- Annoyed: People annoyed\
    \ you about drinking?\n- Guilty: Felt guilty about drinking?\n- Eye-opener: Morning\
    \ drink to steady nerves?\n\nAUDIT (Alcohol Use Disorders Identification Test):\n\
    - 10 questions, score 0-40\n- ≥8 indicates harmful/hazardous drinking\n\nALCOHOL\
    \ WITHDRAWAL:\n\nMinor (6-12h after last drink):\n- Tremor, anxiety, headache,\
    \ nausea, insomnia\n- Diaphoresis, palpitations\n\nMajor (12-48h):\n- Hallucinations\
    \ (visual, auditory, tactile)\n- Withdrawal seizures (6-48h, typically generalized\
    \ tonic-clonic)\n\nDelirium Tremens (48-96h):\n- Altered mental status, severe\
    \ autonomic hyperactivity\n- Hallucinations, agitation, fever\n- Mortality 5-15%\
    \ if untreated\n\nCIWA-Ar Score (Clinical Institute Withdrawal Assessment):\n\
    - Monitors withdrawal severity\n- Score >8: Give benzodiazepines\n\nWITHDRAWAL\
    \ MANAGEMENT:\n1. Benzodiazepines:\n   - Symptom-triggered: Diazepam/lorazepam\
    \ based on CIWA score\n   - Fixed-schedule: Chlordiazepoxide or diazepam taper\n\
    2. Thiamine 100mg IV/IM before any glucose (prevent Wernicke's)\n3. Folate, multivitamin\n\
    4. Supportive care: Hydration, electrolyte repletion\n\nLONG-TERM TREATMENT:\n\
    \n1. PSYCHOSOCIAL:\n   - Motivational interviewing\n   - Cognitive behavioral\
    \ therapy\n   - 12-step programs (AA)\n   - Community reinforcement\n\n2. PHARMACOTHERAPY:\n\
    \   - Naltrexone: Reduces craving and heavy drinking\n   - Acamprosate: Reduces\
    \ craving\n   - Disulfiram: Aversive therapy (acetaldehyde accumulation)\n   -\
    \ Topiramate: Off-label, reduces heavy drinking\n\nCOMPLICATIONS:\n- Hepatic:\
    \ Fatty liver, alcoholic hepatitis, cirrhosis\n- Neurologic: Wernicke-Korsakoff,\
    \ peripheral neuropathy, cerebellar degeneration\n- GI: Pancreatitis, gastritis,\
    \ esophageal varices\n- Cardiac: Cardiomyopathy, arrhythmias\n- Psychiatric: Depression,\
    \ anxiety, suicide risk"
  metadata:
    category: psychiatric
    diagnosis: alcohol_use_disorder
    priority: HIGH
    source: DSM-5, ASAM Guidelines
